TOMSK, Jul 24 – RIA Tomsk. Specialists of the Tomsk сompany "Ifar" finished preclinical tests of drug, which contains the new molecule allowing to regulate coagulability of blood in the safest way; the drug is necessary for the people having cardiovascular diseases, the innovative portal of the Tomsk region reports on Monday.
It is noted that the drugs regulating coagulability of blood are necessary for the people who had strokes, infarcts, installation of stents surgeries, artificial valves. Such patients take antiplatelet drugs all their lives therefore safety of drug is of particular importance.
"We can tell with confidence after tests that we found the effective molecule, which has no competitors on harmlessness yet. This drug is a break for medicine … It influences the mechanism of coagulability of blood differently, than predecessors, affects a signal way which is launched by nitrogen oxide – NO", – the general director of "Ifar" Veniamin Hazanov is quoted in the message.
The molecule, opened by specialists of Ifar influences development of nitrogen oxide in organism, which weakens spasmodic vessels and eliminates the ischemia phenomena. The developers managed to include the molecule in composition of the drug and to prove its efficiency and low toxicity, it is emphasized in the message.It is specified that the drug passed preclinical tests at the moment, prototypes are released. Ifar plans to bring the drug to clinical tests at the end of 2017 – the beginning of 2018.